Ayalew Tefferi, MD
Enriched profileProfessor of Medicine (Hematology), Consultant in Hematology · Mayo Clinic
Ayalew Tefferi is Professor of Medicine (Hematology), Consultant in Hematology at Mayo Clinic. OpenAlex indexes 2,093 publications with 104,476 citations (h-index 154); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology profiles in the findmyKOL directory. Clarivate lists Ayalew Tefferi as a Highly Cited Researcher (Clinical Medicine, 2014, 2016-2021).
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Ayalew Tefferi, M.D., is Professor of Medicine (Hematology), Consultant in Hematology at Mayo Clinic, Rochester, Minnesota (Mayo Clinic College of Medicine and Science, Division of Hematology, Department of Medicine). The public record shows 2,093 publications with 104,476 citations (h-index 154), centered on Myeloproliferative Neoplasms: Diagnosis and Treatment, Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments. It also documents an investigator role on 7 registered clinical trials, 1 NIH-funded awards (1993–1999).
- Most recent indexed publication: 2026 · American journal of hematology
- Top research focus: Myeloproliferative Neoplasms: Diagnosis and Treatment
- 7 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 239 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 1,018.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Sponsor: Sierra Oncology LLC - a GSK company
- A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
Sponsor: Bristol-Myers Squibb
Industry payments
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
94.2%SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor69.3%Remdesivir100%Part B, office-administered≥17 patientsHuman Immunoglobulin G24.9%Immune globulin100%Part B, office-administered≥12 patientsCancer & immunology
5%Janus-associated kinase (JAK) inhibitors2.3%Ojjaara100%Part D≥12 patientsAntimetabolite1.3%Hydroxyurea100%Part D≥13 patientsMetabolism & gastrointestinal
0.4%Corticosteroid0.4%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 1993–1999 per NIH RePORTER. The latest:
- ANTITHYMOCYTE GLOBULIN TREATMENT FOR MYELODYSPLASTIC SYNDROMES
Mayo Clinic Coll of Medicine, Rochester
FY1999M01RR000585 - PHASE I STUDY OF COMBINED CHEMOTHERAPY CONSISTING OF 2-CHLORODEOXYADENOSINE
Mayo Clinic Coll of Medicine, Rochester
FY1994M01RR000585 - PHASE I STUDY OF COMBINED CHEMOTHERAPY CONSISTING OF 2-CHLORODEOXYADENOSINE
Mayo Clinic Coll of Medicine, Rochester
FY1993M01RR000585
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Intensive Induction in AML in the Era of Venetoclax: A Standing Count for "7 + 3"?
American journal of hematology
Article2026 - Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia.
Blood cancer journal
Article2026 - Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities.
American journal of hematology
Letter2026 - Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia.
American journal of hematology
Letter2026 - ICC/WHO-Defined and NGS-Annotated Idiopathic Hypereosinophilia (iHES/iHE): Mutations, Clinical and Treatment Details, and Predictors of Survival.
American journal of hematology
Letter2026
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Facebook
facebook.com/ayalew.tefferi
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗
Mentions by others
where others cite or feature them- Doximity
doximity.com/pub/ayalew-tefferi-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/posts/jamanetwork_author-ayalew-tefferi-of-the-mayo-clinic-activity-7289960451625435136-oYgz
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
bloodcancerstoday.com/podcast/ayalew-tefferi-md-on-risk-stratification-treatment-considerations-for-myelofibrosis
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerstoday.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗
- Board Certified
American Board of Internal Medicine - Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗ - Board Certified
American Board of Internal Medicine - Hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
Editorial & leadership roles
journal and society appointments- Editor-in-Chief
Blood Cancer Journal (Nature Portfolio), alongside co-Editor-in-Chief Vincent Rajkumar
- Associate/Section Editor
American Journal of Hematology, Leukemia, European Journal of Hematology, Hematological Oncology, and Mayo Clinic Proceedings
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayo.edu ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine2014201620172018201920202021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- 2016 Henry M. Stratton Medal for Clinical/Translational Science
American Society of Hematology (ASH), awarded for seminal contributions to clinical/translational hematology research
2016verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hematology.org ↗ - 2008 Emil J. Freireich Medal
University of Texas MD Anderson Cancer Center (highest award for achievement in cancer management) …
2008provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗
Secondary affiliations
appointments beyond the home institution- Listed specialist/contributor
Aplastic Anemia and MDS International Foundation (AAMDSIF) physician directory
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗
Media & interviews
press, podcasts and appearances- "Ayalew Tefferi, MD, on Career Development as a Clinician-Investigator"
Blood Cancers Today podcast
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bloodcancerstoday.com ↗ - "Ayalew Tefferi, MD, on Risk Stratification, Treatment Considerations for Myelofibrosis"
Blood Cancers Today podcast
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bloodcancerstoday.com ↗ - Episode 45
"Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi", Blood Cancer Talks podcast (Spotify)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Rick Nishimura, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic